FDA Panel To Discuss Genentech's Avastin Use In Metastatic Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs panel considers whether progression-free survival can support approval for Avastin absent an overall survival benefit.